Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials.
Therapeutic vaccines for B-cell non-Hodgkin lymphoma (NHL) using the clonal tumour immunoglobulin idiotype (Id) have been under development for more than three decades. A major obstacle for rapid progress in the field has been that the Id vaccine is patient-specific and required the generation of a custom-made product. The manufacturing issues were recently overcome by advances in hybridoma and recombinant DNA technology which facilitated the completion of several phase I and II clinical trials. The strong immunogenicity and apparent clinical benefit observed on the early phase studies led to the initiation of three randomized phase III clinical trials that are also nearing completion. This review will focus on the development of Id vaccines before and after the introduction of rituximab for the treatment of B-cell NHL and also discuss potential strategies to enhance the efficacy of active immunotherapy in the future.
Park
Hyun Jun
HJ
Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
Neelapu
Sattva S
SS
D000917:Antibody Formation; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000276:immunology*; D016233:Immunotherapy, Active; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000276:immunology; D018448:Models, Immunological; D019444:Vaccines, DNA / Q000276:immunology* / Q000627:therapeutic use
D019496:Cancer Vaccines; D007130:Immunoglobulin Idiotypes; D019444:Vaccines, DNA